Navigation Links
Video: CLARITIN Partners with NASCAR Driver Carl Edwards to Educate Motorists on the Importance of Being Clear to Drive(SM)

- Safe Driving Pledge Unveiled as Part of Nationwide Awareness Campaign -

KENILWORTH, N.J., March 18 /PRNewswire-FirstCall/ -- This spring allergy season, Schering-Plough (NYSE: SGP), maker of the non-drowsy allergy medicine, CLARITIN, is continuing its partnership with allergy sufferer and NASCAR driver Carl Edwards to encourage safe driving practices.

To view the Multimedia News Release, go to:

"Drowsy driving is dangerous so I'm participating in the CLARITIN Clear to Drive campaign because I want to make sure people know to check medicine labels for warnings about drowsiness before getting behind the wheel," said Edwards. "As someone who races cars for a living, I can't risk taking an allergy medicine that might make me drowsy. Now I use new CLARITIN(R) Liqui-Gels(R) because it relieves my worst allergy symptoms and it's the only non-drowsy option in an easy-to-swallow liquid-filled capsule."

For the second year in a row, Edwards is the voice of the CLARITIN Clear to Drive(SM) campaign, which aims to prevent drowsy driving and encourages people to stay alert while on the road. This year's campaign asks consumers to take an online pledge and commit to safe driving practices by visiting For every pledge made, the makers of CLARITIN will donate $1 (up to $30,000) to the National Safety Council.

"As a leader in promoting safe driving practices, the National Safety Council supports the CLARITIN Clear to Drive(SM) campaign and its effort to prevent drowsy driving," said Janet Froetscher, president & chief executive of the National Safety Council. "Considering crashes are the number-one cause of accidental death in the U.S., it's important to pay close attention to our driving habits and take the necessary steps to stay alert on the road."

To learn more about drowsy driving and to take the Clear to Drive pledge, visit


All CLARITIN(R) brand products are available without a prescription, including: CLARITIN(R) Tablets, a once-daily, full prescription strength, non-drowsy formulation; CLARITIN(R) RediTabs(R) Tablets, a novel once-daily formulation in a quickly dissolving tablet for ages 6 and older; CLARITIN(R) Liqui-Gels(R), a once-daily formulation in an easy-to-swallow liquid-filled capsule; CLARITIN-D(R) 24-hour and 12-hour Extended Release Tablets, with the decongestant pseudoephedrine, now located behind the counter; CHILDREN'S CLARITIN(R) Syrup, a liquid formulation for children ages 2 and older in grape and fruit flavors; and CHILDREN'S CLARITIN(R) Grape Chewables, a chewable tablet for children ages 2 and older.

CLARITIN(R) is the No. 1 physician-recommended and pediatrician-recommended non-drowsy over-the-counter allergy brand. The CLARITIN(R) Rx-to-OTC switch in 2002 was the largest switch ever-and the first and only for a non-drowsy antihistamine. For more information on allergies and treatment, visit

About Schering-Plough

Schering-Plough Consumer Health Care is the U.S. over-the-counter (OTC) and consumer products business unit of Schering-Plough an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is

SOURCE Schering-Plough
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Video: Record Number of Patients Seek Laser Treatments to Take Light-Years Off Their Faces
2. Video: New Report Card: Nations Mental Health Care System
3. Video: Injectable-Grade Filler, Now Without the Injections
4. Video: Avon Commits Over $1.75 Million for New Partnerships to End Violence Against Women
5. Video: Novalar Announces the Launch of OraVerse(TM) the First Dental Anesthesia Reversal Agent
6. Video: CVS/pharmacy and National Council on Aging Kick Off Medication Management Program for Seniors
7. Video: Facing the Facts - What You Need to Know About Facial Plastic Surgery
8. Video: Majority of Americans Over 45 Experience Joint Pain and Believe it will Affect Their Future Quality of Life
9. Video: The MDS Foundation Says Published Data Confirms VIDAZA(R) Significantly Extends Survival in Patients with the Malignant Condition MDS
10. Video: On 100th Anniversary, Mental Health America Declares Its Time for Mental Health
11. Video: Ear Infections Spark Online Conversations Among Concerned Parents
Post Your Comments:
(Date:11/28/2015)... PA (PRWEB) , ... November 28, 2015 , ... Safe ... the creativity of two inventors, one from Lakewood, New Jersey and the other from ... developed the patent-pending PROTECTOR to save the expense of having to replace NuvaRings more ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published November ... meeting in Washington D.C. revolved around the fact that proper dental care, both at-home ... stressed the link between periodontal disease (more commonly referred to as gum disease) and ...
(Date:11/27/2015)... ... November 27, 2015 , ... An ... way to dispense prescription medications at home, so he invented the patent-pending ELECTRONIC ... and dispense prescription medications. In doing so, it could help to prevent potential ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... innovative online platform for mental health and wellness consultation, has collaborated with a ... will bridge the knowledge gap experienced by parents and bring advice from parenting ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... Nov. 27, 2015  Lannett Company, Inc. (NYSE: ... completed the acquisition of Kremers Urban Pharmaceuticals Inc. ... global biopharmaceuticals company UCB S.A. (Euronext: UCB). ... has acquired KU from UCB for total consideration ... including a customary working capital adjustment, a deduction ...
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... --> --> ... find optimal contrast weighting of MRI for patients with ... a research agreement with SyntheticMR in order to use SyMRI ... is possible to generate multiple contrast images from a single ... left, thus making it possible to both fine tune images ...
Breaking Medicine Technology: